Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Improving Treatment of Ischemic Stroke Using Virtual Thrombectomy (VThrombectomy)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Italy
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2024-01-16
End date: 2026-01-15
Duration (months): 24.0
Total project cost (EUR): 188590.08
EU funding (EUR): 188590.08
Participants: 1
Project status: SIGNED

Acute Ischemic Stroke (AIS) is the leading cause of death and disability globally. In 2017, 1.12 million people suffered from a stroke in European Union, and it is expected to increase by 27% in 2047. The AIS occurred due to insufficient blood supply to the brain from blockage of blood clots or thrombus. Restoration of the blood supply to the brain is the primary objective of medical treatment after the detection of AIS. This can be done using recently developed minimally invasive Endovascular Stroke Treatment (EVT). The introduction of EVT to clinical trials in 2012 revolutionised stroke treatment, but nearly 65% of patients face post-treatment complications and disabilities. Such complications show a huge void in improving the EVT treatment using in silico and in vitro approaches. The current project (VThrombectomy) proposes a framework for mimicking the EVT procedure using in silico approach. The EVT consists of three major components: stent retriever, blood clot, and flexible blood vessel. Mimicking these components for numerical simulations and understanding the mechanical forces involved is the primary objective of this project. In which, Patient-based images will be used to mimic the cerebral arterial network, and mechanical properties of thrombus will be replicated using patient-based clot stress-strain data. The development of a virtual thrombectomy procedure will take place by solving these components using a multiphysics approach in a coupled way. The major limitations involved in the previous studies were the use of an ideal cerebral artery model with rigid walls and the absence of blood flow during EVT. VThrombectomy proposes to address these limitations by the inclusion of patient-specific flexible blood vessels with flowing blood. Parametric analysis of EVT using in silico approach can dive deep into the treatment and improves our understanding of the mechanical forces involved, which results in improved and efficient devices to retrieve the clot.

Keywords: cardiovascular flows,cerebrovascular flows,structural mechanics,virtual thrombectomy,stent retriever,thrmbus modeling
DIGITAL TRANSFORMATION IN PORT MANAGEMENT (iEstiba)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Spain
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 1665981.0
EU funding (EUR): 1665981.0
Participants: 1
Project status: SIGNED

iEstiba is an innovative technological solution on digital twin basis that creates a digital market in port management. The iEstiba approach is UNIQUE; there is no other solution on the market capable of global port-logistics management. iEstiba brings more intelligence and efficiently organizes port system resources with the use of AI, big data and blockchain to automate shifts, manage demand in real time and perform predictive analysis. iEstiba solves current operational problems while preparing ports to face future challenges through smarter, data-driven management. This solution represents a paradigm shift in the way ports can operate with greater intelligence, agility and a focus on sustainability. Thanks to this solution, a digital and innovative market is created in a traditional and strategic sector in the European Union. In addition, the innovative technological solution iEstiba contributes to the comprehensive European Port Strategy as a platform that promotes competitiveness and logistics planning of ports by incorporating a digital solution based on innovative technologies to provide ports with intelligence and sustainable management. iEstiba has already been tested in real environments and improvements are being developed in order to start marketing the product, thus complying with the deadlines established by the European Parliament's resolution. Through EIC project funding, iEstiba aims to reduce uncertainty by getting closer to the market and attracting the new investors needed for the subsequent growth and expansion phase. In addition, the EU support would achieve two key objectives for the iEstiba project, improving the profitability of the project and attracting private investment.

Keywords: port management
Pioneering antibody-drug conjugates targeting the tumour microenvironment to deliver transformative new therapies in oncology (ONCO-DART)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Spain
Call: EIC Accelerator Open 2025 (HORIZON-EIC-2025-ACCELERATOR-02, 2025)
Start date: 2025-11-01
End date: 2027-10-31
Duration (months): 24.0
Total project cost (EUR): 3570537.0
EU funding (EUR): 2499375.9
Participants: 1
Project status: SIGNED

Oncomatryx Biopharma SL (ONCOMATRYX) is a cutting-edge biotechnology company established in 2010 in Bilbao, Spain, with the mission to pioneer and develop novel precision drugs targeting the tumour microenvironment for indications of high unmet need. We strive to change the paradigm in the treatment of some of the most aggressive metastatic solid tumors, by neutralizing the immunosuppressive influence of the tumour microenvironment on cancer cells. To achieve this goal, we have developed a comprehensive pipeline of antibody-drug conjugates (ADCs) and human-derived proteins targeting stroma cells in the tumor microenvironment. Our lead candidate, OMTX705, has demonstrated promising safety and efficacy in preclinical models and is currently undergoing Phase I clinical trials for colorectal, pancreatic, lung, and sarcoma cancers. The global market for ADCs is expanding rapidly, with a projected $140 billion opportunity over the next 15 years. ONCOMATRYX aims to leverage this growth through a business strategy focused on out-licensing its assets to pharmaceutical partners for large-scale clinical development and commercialization. The company has already secured a licensing agreement with InxMed for the East Asian market and anticipates a €700M licensing deal for North America, Europe, and Japan upon successful completion of Phase II trials. To advance OMTX705 into Phase Ib and II clinical trials, ONCOMATRYX seeks EIC Accelerator funding, combining a €2.5M grant and a €10M equity investment. This funding will enable parallel execution of Phase Ib studies, accelerate clinical development, and strengthen the company’s market positioning for strategic partnerships. Ultimately, EIC support will be instrumental in achieving key milestones, securing major licensing deals, and driving ONCOMATRYX’s long-term success in transforming cancer treatment.

Keywords: antibody drug conjugates,tumor microenvironment
Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours (IMPACT)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2024-12-01
End date: 2026-11-30
Duration (months): 24.0
Total project cost (EUR): 3569615.0
EU funding (EUR): 2498730.5
Participants: 1
Project status: SIGNED

UTUC is a non-systemically treatable cancer that forms in the renal pelvis or ureter, frequently recurring due to ineffective systemic chemotherapy. With 5-10% of urothelial cancers being UTUC, current surgical treatment solutions pose significant hardships on patients and decrease their quality of life. Our proprietary solution, Padeliporfin-VTP therapy, offers a minimally invasive and effective alternative to surgery. This therapy delivers an inactive photosensitizer drug that is precisely activated in the tumour micro-environment by non-thermal laser light, immediately impeding the tumour's blood supply, leading to cell death with minimal effect on healthy tissues. This treatment not only effectively eliminates tumours, but also preserves organ functionality for potential future treatments. This project is led by a team of accomplished professionals in the pharmaceutical and biopharma industry, which solidifies our capability in innovating best-in-class therapeutic solutions. Utilising this funding, we aim to achieve regulatory approval (TRL9), scale production, and achieve market penetration in a market projected to reach €4.39B by 2032.

Keywords: immune modulation,upper tract urothelial carcinoma,pdac,solid tumours,urothelial cancers
Science-based test for personalised metabolic health score to transform lifestyle (Lipodoo)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Germany
Call: EIC Accelerator 2025 - Short application (HORIZON-EIC-2025-ACCELERATOR-01, 2025)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Lipotype, founded in 2012, is the leading provider of lipidomics analysis services worldwide. Our mass spectrometry-based technology identifies and quantifies over 4200 lipid species, offering high-throughput, rapid quantitative analysis from minute sample amounts. Despite the emphasis on wellness products, the obesity pandemic continues to burden global health, with nearly 60% of the EU population and 42% of the US adult population classified as obese or overweight. This is linked to various non-communicable diseases, including type 2 diabetes and cardiovascular diseases, leading to escalating annual healthcare costs of 70B€ in the EU and reduced productivity. Lipotype addresses this issue with the Lipodoo test, a lipidomics-based blood test that measures metabolic health. Lipodoo leverages advanced mass spectrometry and machine learning algorithms to provide a comprehensive assessment of an individual's metabolic state. The test is designed for at-home use, where users can collect a dried blood spot sample and send it to Lipotype for analysis. The results are integrated with health apps, providing users with a personalized metabolic health score that is easily interpretable. This innovative approach offers a detailed snapshot of metabolic health and empowers individuals to make actionable interventions about their lifestyle. Lipodoo has the potential to revolutionize preventative healthcare by enabling early detection of obesity risk and interventions for a healthier lifestyle. By providing actionable insights into metabolic health, Lipodoo can help reduce the incidence of obesity-related diseases, improve lifestyle, and lower healthcare costs. As a B2B2C product, Lipodoo is expected to significantly impact individuals using health apps, public health, and academic research. Overall, Lipodoo offers significant advancement in metabolic health monitoring, with the potential to improve the healthspan of individuals globally and make a substantial impact on health.

Keywords: lipids,lipidomics,mass spectrometry,science based test,metabolism,metabolic health score,digital health
Open Generative AI platform for Healthcare (GENESIS AI)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Netherlands
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Our project GENESIS AI represents a pivotal advancement in healthcare technology, leading the development of an open-source generative AI platform that revolutionizes healthcare delivery. The project will be led by Healthsage AI, founded by visionaries Harm-Jan Wessels and Marcel Alberti, who bring over 30 years of entrepreneurship and industry experience. The GENESIS AI project combines cutting-edge technology with profound healthcare insights to transform patient and provider experiences. Central to its innovation is the HealthSage AI foundational generative platform and our flagship application Note-to-FHIR converts unstructured clinical data into structured information compliant with Fast Healthcare Interoperability Resources standards, improving data interoperability and enhancing clinical decision-making.This exemplifies the platform's capability to streamline healthcare processes, making patient data more accessible and actionable. The HealthSage AI platform adheres strictly to the EU’s AI Act, ensuring the platform prioritizes security, patient privacy, and ethical AI usage. Its architecture is scalable and robust, designed to meet the global healthcare industry's demands while adhering to stringent data and regulatory protection standards. Supported by the EIC, the GENESIS AI project will drive innovations that offer predictive analytics, personalized patient engagement, and efficient clinical workflows. By providing advanced AI tools, the GENESIS AI project enhances healthcare delivery efficiency, addresses data fragmentation, and eases the increasing burden on healthcare systems. HealthSage AI's GENESIS AI project is set to transform the healthcare landscape by delivering a secure, compliant AI platform that enables universal data access and revolutionizes healthcare practices worldwide. Backed by a team renowned for their expertise and commitment to digital health innovation, this initiative marks a significant leap forward in healthcare technology.

Keywords: generative ai foundational models ai platform
A New Labour Law for Supply Chain Capitalism (New Labour Law)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Institutions, Governance and Legal Systems
Panel description: Political science, international relations, law
Countries involved: Israel
Call: ERC CONSOLIDATOR GRANTS (ERC-2022-COG, 2022)
Start date: 2024-09-01
End date: 2029-08-31
Duration (months): 60.0
Total project cost (EUR): 1997511.0
EU funding (EUR): 1997511.0
Participants: 1
Project status: SIGNED

Labour law gradually protects fewer of the worlds’ workers. Changes in work and capital structure, new technologies and evolving modes of supply and production (together: ‘supply chain capitalism’), lead to an incongruence between the distribution of market power and the premises and tools of labour law, creating barriers to workers’ organization and agency. This incongruence stems from the fact that labour law developed in industrial economies to respond to the power disparities between capital and labour, and is therefore tied to a dyadic employer-employee paradigm in which labour law seeks to empower workers vis-à-vis employers, the presumed owners of capital. Yet this is no longer the case in the era of supply chain capitalism, where the direct employer is often a supplier in a Global Value Chain (GVC), whose economic calculus is dependent on corporations in higher tiers of the chain. Given the crises of both labour law and GVC governance, this project offers a path to restructure labour law to fit new patterns of supply chain capitalism. The project includes three main components: 1) Theoretical: The project intervenes in existing literature and theory on GVC governance and on labour law to propose a new analytical framework for reconceptualizing the role of workers and of labour law in GVC governance. 2) Empirical: Current initiatives to improve workers’ rights in GVCs worldwide are based mostly on voluntary schemes, often perceived as ‘private’ or rooted in ‘soft-law’. The project will closely study existing initiatives and holistically analyse the studies development and examine whether and how labour law can be restructured to support existing successful initiatives and produce new sustainable paths to strengthen worker power in GVCs. 3) Normative: Based on the two preceding parts, the project will create a blueprint for a new, and overdue, labour law for supply chain capitalism.

Keywords: labour law,work and employment,global value chains,supply chains,sweatshops,worker organizing,transnational coalitions
Photosynthetic Antennas in a Computational Microscope: Training a new generation of computational scientists (PhotoCaM)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Doctoral Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Greece,Italy,Netherlands,Lithuania,Spain,Austria,France,Poland
Call: MSCA Doctoral Networks 2022 (HORIZON-MSCA-2022-DN-01, 2022)
Start date: 2024-01-01
End date: 2027-12-31
Duration (months): 48.0
Total project cost (EUR): 2822661.26
EU funding (EUR): 2589847.2
Participants: 12
Project status: SIGNED

Photosynthesis relies on harvesting the sun light and on transforming the solar energy into chemical energy to sustain almost all life on earth. An enhanced molecular-level understanding of photosynthesis and particularly of the light-harvesting process is of key significance: Firstly, a molecular-level understanding of solar light harvesting and how plants and other organisms achieve this is important if we want to figure out the working principles of nature. From this, we can learn design principles of (organic) solar cells. Secondly, controlling the downregulation of photosynthesis is seen as a strategy for the optimization of crop productivity especially by means of novel tools and biotechnological solutions. In the Doctoral Network “Photosynthetic Antennas in a Computational Microscope” we aim at training a new generation of computational scientists which can treat complex and interdisciplinary problems such as light harvesting on a molecular level using theoretical and computational tools. The interdisciplinary nature of the problem requires a combined knowledge from biology, chemistry, physics and computer science in order to combine state-of-the-art approaches like molecular dynamics simulations, quantum chemistry, theoretical spectroscopy and machine learning into multi-scale schemes. This joint undertaking is a unique chance in research but especially also in training young scientists in interdisciplinary teamwork, method training and high-performance computing in academic as well as non-academic settings. Aim of the Doctoral Network is a detailed molecular understanding of light harvesting from the computational point of view and especially of the downregulatory mechanisms of photosynthesis present in higher plants and diatoms. While the undertaking exclusively focuses on theoretical and computational approaches, the calculation of spectroscopic properties for a direct comparison to experimental findings is of key importance.

Keywords: light harvesting,photoprotection,molecular level multi scale approaches including machine learning
Combining catalyst design and electrode reconstruction for industry compatible CO2 electrolysis (HPSR-AME-CO2RR)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Denmark
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2024-06-01
End date: 2026-05-31
Duration (months): 24.0
Total project cost (EUR): 230774.4
EU funding (EUR): 230774.4
Participants: 1
Project status: TERMINATED

Anthropogenic CO2 emission is anticipated to contribute to a projected global temperature increase of 1.5°C between 2030 and 2052, which is associated with various environmental challenges. While renewable energy sources and electrification have successfully reduced CO2 emissions in some sectors, air transportation without available electrified alternatives and sectors like steel and cement production that inherently involve carbon oxidation in operations must proactively take measures to mitigate their carbon footprint. This entails a combination of adopting renewable fuels and employing CO2 conversion techniques. In the short to intermediate term, the renewable-powered electrochemical CO2 reduction reaction (eCO2RR) for carbon monoxide production offers a techno-economically feasible approach. Despite extensive research efforts in this field, achieving economically compelling eCO2RR implementation has proven elusive. The primary challenges stem from catalyst performance and electrode durability. Regarding catalysts, maintaining high selectivity under commercially relevant conditions is imperative. On the electrode front, enhancing both chemical and mechanical strength is essential to reduce capital expenditure. To comprehensively address these challenges and with the support of the Marie Skłodowska-Curie Actions, the objective of this project is to integrate electrocatalyst design (focused on improving eCO2RR selectivity and activity) with electrode reconstruction efforts (aimed at overcoming flooding issues and enhancing the stability of the reaction interface). This integrated approach seeks to facilitate the practical implementation of eCO2RR. Furthermore, a deep understanding of the structure-activity relationship will be attained through in-situ spectroscopy and theoretical calculations. The assessment of this novel strategy within this project's scope has the potential to guide the more rational development of practical eCO2RR implementation.

Keywords: single atom catalysts,3d self supporting electrode,co2 reduction reaction,electrocatalysis